CompletedPhase 1

Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

Italy16 participantsStarted 2007-11

Plain-language summary

The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.

Who can participate

Age range35 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Myopic CNV, CNV leakage Exclusion Criteria: * CNV not associated with high myopia * No activity of CNV

What they're measuring

BCVA improved

Timeframe: 6 months

Trial details

NCT IDNCT00802126

SponsorUniversity of Campania Luigi Vanvitelli

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-12

View on ClinicalTrials.gov More Myopia trials